<DOC>
	<DOCNO>NCT00044902</DOCNO>
	<brief_summary>Epratuzumab currently study combination rituximab , treatment patient low-grade NHL fail previous chemotherapy never receive rituximab receive rituximab single agent combination chemotherapy last treatment demonstrate partial response complete response least 12 month .</brief_summary>
	<brief_title>Monoclonal Antibody Treatment Non-Hodgkin 's Lymphoma ( Low-Grade )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Diagnosis relapse refractory lowgrade , CD20+ , Bcell NHL * Received fail least 1 prior regimen chemotherapy * Rituximabnaive receive prior rituximab last treatment ( single agent combination chemotherapy ) demonstrate time progression least 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>